BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250613T133000
DTEND;TZID=Europe/Vienna:20250613T143000
DTSTAMP:20260421T181746
CREATED:20241017T081027Z
LAST-MODIFIED:20250605T095541Z
UID:1934-1749821400-1749825000@esmit.eanm.org
SUMMARY:Cardiac Amyloidosis Imaging: Do We Need Quantification?
DESCRIPTION:This webinar provides an overview of the diagnosis of cardiac amyloidosis in nuclear cardiology . Background information on amyloidosis in general is presented and typical disease manifestations are discussed. Furthermore\, the significance of cardiac amyloidosis will be discussed in detail and possible therapeutic options will be explained. In this context\, the relevance of quantification to characterize disease and how to assess reliably the effects of therapy are presented. \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo gain a insight into the disease of amyloidosis and in particular the cardiac involvement of amyloidosis.\n\n\n\nTo learn the possibilities of quantification of planar and SPECT studies in amyloidosis\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear physicians\, cardiologists\, internists and radiologists who are interested in amyloidosis and want to deepen their knowledge of cardiac amyloidosis diagnostics and quantification\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nFederico CaobelliSpeaker \n\n\n\n\n\nIan ArmstrongSpeaker \n\n\n\n\n\nCarmela NappiModerator \n\n\n\n\n\nStephan NekollaModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/cardiac-amyloidosis-imaging-do-we-need-quantification/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250627T133000
DTEND;TZID=Europe/Vienna:20250627T143000
DTSTAMP:20260421T181746
CREATED:20241017T080743Z
LAST-MODIFIED:20250624T092530Z
UID:1932-1751031000-1751034600@esmit.eanm.org
SUMMARY:Extravascular Administration in Diagnostic and Therapeutic Nuclear Medicine
DESCRIPTION:In nuclear medicine\, diagnostic as well as therapeutic\, radiopharmaceuticals are administered via an intravenous injection\, in a majority of the procedures in a blood vessel at the crook of the arm or on the back of the hand. Occasionally\, the injection fails\, which results in the radiopharmaceutical ending up extravascularly. The consequence of this may be a locally high radiation dose at the injection site\, in some situations high enough to cause severe tissue effects on the patient. Thus\, it is important to recognize the problem and identify the cause in order to decrease the risk. Furthermore\, the management of the situation after such an extravasation must be dealt with thoroughly and this has been the subject of lively debate in recent years. The parameters that have an impact on the radiation dose are among other things\, the physical properties of the radionuclide\, as well as the activity and volume of the radioactive substance retained in the surroundings of the blood vessel. In the case when most of the administered activity ends up extravascular\, the quality of the diagnostic procedure or the effect of the treatment are negatively affected\, which must be addressed. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\nThe aim of this webinar is to highlight the risk and consequences of extravascular administration of radiopharmaceuticals as well as the management of the situation after an extravasation. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nPhysicists\, Physicians\, Technologists\, Nurses \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSiria MediciSpeaker \n\n\n\n\n\nJochem van der Pol Speaker \n\n\n\n\n\nSigrid Leide SvegbornModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/extravascular-administration-in-diagnostic-and-therapeutic-nuclear-medicine/
CATEGORIES:Instrumentation, Technology, Science,Live Webinars
END:VEVENT
END:VCALENDAR